刘东刚

[摘要] 目的 探讨康莱特注射液联合化疗治疗晚期非小细胞肺癌合并糖尿病的效果。方法 选取2015年3月—2018年3月该院收治的58例晚期NSCLC合并糖尿病患者，随机分为两组，各29例，对照组给予NP化疗方案，观察组在对照组的基础上给予康莱特注射液。结果 观察组总有效率为79.3%，不良反应发生率为27.6%，明显优于对照组62.1%、41.4%，差异有统计学意义（P<0.05）；观察组FPG、2 hPG明显低于对照组，差异有统计学意义（P<0.05）。结论 康莱特注射液联合化疗治疗晚期NSCLC合并糖尿病，能有效提高治疗效果，减少不良反应。

[关键词] 康莱特；晚期非小细胞肺癌；糖尿病

[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062（2018）08（b）-0075-02

Clinical Study of Kanglaite Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer with Diabetes

LIU Dong-gang

Department of Oncology， Changchun Central Hospital， Changchun， Jilin Province， 130000 China

[Abstract] Objective To investigate the effect of Kanglaite injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer with diabetes mellitus. Methods A total of 58 patients with advanced NSCLC complicated with diabetes mellitus admitted to the department from March 2015 to March 2018 were randomly divided into two groups， with 29 patients in each group. The control group was given NP chemotherapy. The observation group was given Kanglaite injection on the basis of the control group. Results The total effective rate of the observation group was 79.3%， and the incidence of adverse reactions was 27.6%， which was significantly better than that of the control group（62.1%，41.4%），the differeent was statistically significant（P<0.05）. The FPG and 2 hPG in the observation group were significantly lower than those in the control group，the differeent was statistically significant（P<0.05）. Conclusion Kanglaite injection combined with chemotherapy in the treatment of advanced NSCLC with diabetes can effectively improve the treatment effect and reduce adverse reactions.

[Key words] Kanglaite； Advanced non-small cell lung cancer； Diabetes

近年來，癌症合并糖尿病的发病率越来越高。大量流行病学研究显示[1]，糖尿病与许多种恶性肿瘤具有关联性，糖尿病可通过多种生物学机制影响着肿瘤的发生发展。肺癌是临床常见的恶性肿瘤，其发病率和致死率均较高，据卫计委癌症登记中心资料显示[2]，我国每年新增肺癌患者60多万，死亡人数超过50万。当肺癌与糖尿病合并发生时，两种疾病常相互影响，相互恶化，严重影响了患者的预后和生命。选取该科2015年3月—2018年3月采取康莱特注射液联合化疗治疗的29例晚期非小细胞肺癌（NSCLC）合并糖尿病患者，探讨康莱特注射液配合化疗对晚期NSCLC合并糖尿病患者的疗效，现报道如下。

1 资料与方法

1.1 一般资料

选取该科收治的58例晚期NSCLC合并糖尿病患者为观察对象，均经病理学或细胞学检查确诊。随机将患者分为两组，各29例，观察组男20例，女9例，年龄45～78岁，平均年龄（57.9±2.6）岁，糖尿病病程2～11年，平均病程（5.6±1.2）年；病理类型：腺癌13例，鳞癌12例，腺鳞癌4例。对照组男19例，女10例，年龄47～76岁，平均年龄（58.2±3.0）岁，糖尿病病程2～10年，平均病程（5.4±1.0）年；……